stockportfolio.pro
Ardelyx, Inc. (ARDX)
Healthcare · Biotechnology · NasdaqGM
Ardelyx, Inc. revenue & earnings — last 10 fiscal years
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $42.00M | $2.61M | $5.28M | $7.57M | $10.10M | $52.16M | $124.46M | $333.62M | $407.32M |
| Gross profit | — | $33.60M | $2.14M | $4.68M | $7.43M | $9.10M | $48.04M | $106.66M | $283.06M | $367.78M |
| Net income | $-112.39M | $-64.34M | $-91.30M | $-94.94M | $-94.31M | $-158.16M | $-67.21M | $-66.07M | $-39.14M | $-61.60M |
| Net margin | — | -153.2% | -3502.0% | -1797.8% | -1245.7% | -1566.5% | -128.9% | -53.1% | -11.7% | -15.1% |
Source: Ardelyx, Inc. SEC filings (10-K). 14 years of history available in the interactive view.
Explore 14 years of Ardelyx, Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track ARDX in your portfolio →
Ardelyx, Inc. financial history by metric
About Ardelyx, Inc.
Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally. The company offers IBSRELA, a minimally absorbed small molecule therapy for the treatment of patients with irritable bowel syndrome with constipation; and XPHOZAH, a phosphate absorption inhibitor to reduce serum phosphorus in adults with chronic kidney disease on dialysis. Ardelyx, Inc. was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. The company was incorporated in 2007 and is headquartered in Waltham, Massachusetts.
Ardelyx, Inc. — frequently asked questions
What is Ardelyx, Inc.'s revenue?
Ardelyx, Inc. (ARDX) reported revenue of $407.32M for fiscal year 2025, up 22.1% from the prior year, according to its SEC filings.
Is Ardelyx, Inc. profitable?
No — ARDX reported a net loss of $-61.60M in fiscal 2025.
What is ARDX's P/E ratio?
Ardelyx, Inc. trades at a price-to-earnings ratio of about 0.0 based on the latest data in our nightly-refreshed cache.
How fast is Ardelyx, Inc. growing?
ARDX's revenue grew at roughly 121.9% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
How much debt does Ardelyx, Inc. have?
As of fiscal year 2025, ARDX carried roughly $202.83M in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Ardelyx, Inc.'s gross margin?
ARDX's gross margin was 90.3% in fiscal 2025 — gross profit of $367.78M on revenue of $407.32M.
What is Ardelyx, Inc.'s market cap?
Ardelyx, Inc. (ARDX) has a market capitalization of about $1.44B, based on the latest data in our nightly-refreshed cache.
When does Ardelyx, Inc.'s fiscal year end?
ARDX's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
Where does this data come from?
All figures are computed from Ardelyx, Inc.'s official SEC filings (10-K and 10-Q), covering 14 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.